Intravenous Immunoglobulin (IVIg) with Methylprednisolone Pulse Therapy for Motor Impairment of Neuralgic Amyotrophy: Clinical Observations in 10 Cases
Intravenous Immunoglobulin (IVIg) with Methylprednisolone Pulse Therapy for Motor Impairment of Neuralgic Amyotrophy: Clinical Observations in 10 Cases
复制标题
DOI：
10.2169/internalmedicine.51.7049
复制
发表时间：
2012-01-01
影响因子：
1.2
通讯作者：
Ikeda, Shu-ichi
中科院分区：
文献类型：
--
作者：
Naito, Ko-suke;Fukushima, Kazuhiro;Ikeda, Shu-ichi
神经痛性肌萎缩（Neuralgic amyotrophy，NA）是一种以急性神经病理性疼痛发作和上肢快速多灶性无力和萎缩为特征的外周神经系统疾病。目前的假设是，发作是由免疫介导的反应，臂丛神经，然而，治疗策略NA还没有得到很好的established.Methods和结果我们回顾性分析了15例系列NA; 15例患者中有10例接受静脉注射免疫球蛋白（IVIg）和甲基强的松龙冲击治疗（MPPT）结论IVIg联合MPPT可能是治疗NA的有效方法之一，但其疗效仍有待进一步证实。需要在不同临床严重程度和NA分期的患者中进行进一步的确证性试验。应进行进一步的基础研究和验证性试验，以调查这种免疫调节治疗NA的疗效。
Background Neuralgic amyotrophy (NA) is a distinct peripheral nervous system disorder characterized by attacks of acute neuropathic pain and rapid multifocal weakness and atrophy unilaterally in the upper limb. The current hypothesis is that the episodes are caused by an immune-mediated response to the brachial plexus, however, therapeutic strategies for NA have not been well established.Methods and Results We retrospectively reviewed 15 case series of NA; 10 of the 15 patients received intravenous immunoglobulin (IVIg) with methylprednisolone pulse therapy (MPPT) and 9 of these10 patients showed clinical improvement of motor impairment.Conclusion Our clinical observations do not contradict the possibility that IVIg with MPPT may be one of the potential therapeutics for NA, however the efficacy remains to be established. Further confirmatory trials are needed in patients with various clinical severities and phases of NA. Further basic research and confirmatory trials should be performed to survey the efficacy of such immunomodulation therapy for NA.